Heartburn efficacy study
This article was originally published in The Tan Sheet
Executive SummaryOut of nearly 2,000 study participants and GERD sufferers in Europe and the U.S., those who took prescribed proton pump inhibitors were more likely to have improved symptoms than those whose symptoms were undiagnosed and took OTC remedies, according to a study presented during Digestive Disease Week May 14-19 in Chicago. Roger Jones, Guy's King's and St. Thomas School of Medicine, et al., used a 100-item questionnaire to identify participants. "Of undiagnosed sufferers taking OTC medicines, 81% still suffered some symptoms compared with 68% of diagnosed patients taking prescription drugs and 69% of diagnosed patients taking PPIs," the study states. Astrazeneca, marketer of prescription Nexium, provided funding for the study...
You may also be interested in...
While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.
Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.
First Circuit reverses dismissal of direct purchasers' suit alleging improper listing of patent on device drive mechanism delayed competition; district court to decide if this constitutes antitrust violation.